New drug combo tested to control Tough-to-Treat blood cancer

NCT ID NCT03180736

Completed Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding a drug called daratumumab to a standard two-drug treatment (pomalidomide and dexamethasone) works better for people with multiple myeloma that has come back or stopped responding to prior treatments. It involved 304 adults whose cancer had progressed after previous therapies. The main goal was to see if the three-drug combination could keep the cancer from getting worse for a longer time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Ancona

Ancona, Italy
Anticancer Hospital of Thessaloniki "Theageneio"

Thessaloniki, Greece
Antwerpen

Antwerp, Belgium
Badalona

Badalona, Spain
Barcelona

Barcelona, Spain
Belgrade

Belgrade, Serbia
Bologna

Bologna, Italy
Brescia

Brescia, Italy
Brno

Brno, Czechia
Brussel

Brussels, Belgium
Capa

Çapa, Turkey (Türkiye)
Cebeci

Cebeli, Turkey (Türkiye)
Doctor Peset University Hospital Medical Centre

Valencia, Spain
Erasmus MC

Rotterdam, Netherlands
Freiburg

Freiburg im Breisgau, Germany
Gaziantep

Gaziantep, Turkey (Türkiye)
General Hospital of Athens "Evangelismos"

Athens, Greece
General University Hospital of Patras

Pátrai, Greece
Hamburg

Hamburg, Germany
Heidelberg

Heidelberg, Germany
Hospital Quirón Salud Madrid

Madrid, Spain
Hospital Universitario de la Princesa

Madrid, Spain
Izmir

Izmir, Turkey (Türkiye)
Kayseri

Kayseri, Turkey (Türkiye)
Kiel

Kiel, Germany
Milano

Milan, Italy
Odense

Odense, Denmark
Ostrava

Ostrava, Czechia
Praha 2

Prague, Czechia
Roma

Roma, Italy
Salamanca University Hospital

Salamanca, Spain
Schwerin

Schwerin, Germany
Torino

Torino, Italy
Tübingen

Tübingen, Germany
UZ Gent

Ghent, Belgium
University of Athens School of Medicine

Athens, Greece
VU MC

Amsterdam, Netherlands
Vejle

Vejle, Denmark
Würzburg

Würzburg, Germany
Yvoir

Yvoir, Belgium

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA